Key result
High-dominant frequency and continuous CFAE site ablation improved 12-month freedom from AF/AT recurrence compared to external cardioversion in patients with induced arrhythmias after PVI (91% vs 64%, P=0.033).
Why the study?
Does atrial substrate modification based on dominant frequency and CFAE improve freedom from AF/AT recurrence in PAF patients with inducible arrhythmia after PVI?
Cohort (n=122)
Does atrial substrate modification based on dominant frequency and CFAE improve freedom from AF/AT recurrence in PAF patients with inducible arrhythmia after PVI?
In patients with paroxysmal AF and residual arrhythmia inducibility after PVI, additional atrial substrate ablation targeting high-dominant frequency and CFAE sites significantly improves freedom from arrhythmia recurrence compared to cardioversion alone.
BACKGROUND: The endpoint of ablation procedures is suggested to be non-inducibility of paroxysmal atrial fibrillation (PAF). However, the prognosis of induced AF/atrial tachycardia (AT) after pulmonary vein isolation (PVI) in PAF patients remains unclear. METHODS: A total of 122 PAF patients were divided into the following 3 groups: Group 1, 79 without AF/AT induced after PVI; Group 2, 21 with AF/AT induced or sustained after PVI, and followed by a high-dominant frequency (DF) and continuous complex fractionated atrial electrogram (CFAE) site ablation and, if necessary, linear ablation; and Group 3, 22 with external cardioversion of AF/AT induced or sustained after PVI. High-DF (DF≥8 Hz) and continuous CFAE (fractionated intervals≤50 ms) sites were targeted. The ablation endpoint was non-inducibility of PAF. RESULTS: In Group 2, AF terminated in 2 patients with a high-DF and continuous CFAE site ablation. In 4 patients, AF induced after cardioversion did not terminate with left atrium linear ablation, and required additional cardioversion. Common atrial flutter in 2 patients terminated with cavotricuspid isthmus ablation. An AT terminated with a roofline ablation. Finally, no AF/AT could be induced in any of the patients in Group 2 after all the procedures. The cumulative freedom from AF/AT recurrence without antiarrhythmic drugs in Groups 1 and 2 was significantly greater than that in Group 3 after 1 procedure during 12 months of follow-up (90% and 91% vs. 64%, Log-rank test P=0.001 and P=0.033, respectively). CONCLUSIONS: Atrial substrate ablation may improve the clinical outcome after ablation in patients after PVI with residual arrhythmia inducibility.
No takes yet. Share an insight, caveat, or question.
Kumagai et al. (2016) conducted a cohort in Paroxysmal atrial fibrillation (n=122). High-dominant frequency and continuous CFAE site ablation vs. External cardioversion was evaluated on Cumulative freedom from AF/AT recurrence without antiarrhythmic drugs (p=0.033). High-dominant frequency and continuous CFAE site ablation improved 12-month freedom from AF/AT recurrence compared to external cardioversion in patients with induced arrhythmias after PVI (91% vs 64%, P=0.033).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: